



Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

September 24, 2018

CINCINNATI--(BUSINESS WIRE)--Sep. 24, 2018-- Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at <http://ir.aerpio.com/>.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information, please visit www.aerpio.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180924005069/en/>

Source: Aerpio Pharmaceuticals, Inc.

Investor & Media:

Aerpio Pharmaceuticals, Inc.

Michael Rogers

Chief Financial Officer

mrogers@aerpio.com

or

Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.

Media:

Robert Flamm, Ph.D.

rflamm@burnsmc.com

or

Investors:

Ami Bavishi

abavishi@burnsmc.com